0000000000201029

AUTHOR

Edmund Kostewicz

showing 2 related works from this author

In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration

2019

The availability of in vitro tools that are constructed on the basis of a detailed knowledge of key aspects of gastrointestinal (GI) physiology and their impact on formulation performance and subsequent drug release behaviour is fundamental to the success and efficiency of oral drug product development. Over the last six years, the development and optimization of improved, biorelevant in vitro tools has been a cornerstone of the IMI OrBiTo (Oral Biopharmaceutics Tools) project. By bringing together key industry and academic partners, and by linking tool development and optimization to human studies to understand behaviour at the formulation/GI tract interface, the collaboration has enabled …

Process managementUPPER GASTROINTESTINAL-TRACTAdministration OralPharmaceutical Science02 engineering and technologyWATER DIFFUSIVITYModels Biological030226 pharmacology & pharmacyDosage formBiopharmaceutics03 medical and health sciences0302 clinical medicineDISINTEGRATION TESTERHumansPharmacology & PharmacyWEAK BASESIntersectoral CollaborationBiologyTEST DEVICEDosage FormsALBENDAZOLE CONCENTRATIONSScience & TechnologyHuman studiesbusiness.industryBiopharmaceuticsFED STATE CONDITIONSGeneral Medicine021001 nanoscience & nanotechnologyRELEASE TABLETSGastrointestinal TractPharmaceutical PreparationsGastrointestinal AbsorptionGeneral partnershipSOLID DISPERSIONNew product developmentDrug releaseIntersectoral Collaboration0210 nano-technologybusinessLife Sciences & BiomedicineUPPER SMALL-INTESTINEOral retinoidForecastingBiotechnology
researchProduct

IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and ov…

2016

Orally administered drugs are subject to a number of barriers impacting bioavailability (Foral), causing challenges during drug and formulation development. Physiologically-based pharmacokinetic (PBPK) modelling can help during drug and formulation development by providing quantitative predictions through a systems approach. The performance of three available PBPK software packages (GI-Sim, Simcyp®, and GastroPlus™) were evaluated by comparing simulated and observed pharmacokinetic (PK) parameters.Since the availability of input parameters was heterogeneous and highly variable, caution is required when interpreting the results of this exercise. Additionally, this prospective simulation exer…

Physiologically based pharmacokinetic modellingChemistryBiopharmaceuticsDrug Evaluation PreclinicalArea under the curveAdministration OralPharmaceutical ScienceModels Biological030226 pharmacology & pharmacyBiopharmaceuticsBioavailabilityClinical studyToxicology03 medical and health sciences0302 clinical medicineIntestinal AbsorptionPharmaceutical PreparationsPharmacokineticsCompounding030220 oncology & carcinogenesisStatisticsHumansComputer SimulationImmediate releaseForecastingEuropean Journal of Pharmaceutical Sciences
researchProduct